Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficac ....Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.Read moreRead less
Treating tuberculosis: targeted delivery of multidrug nano-suspensions. Tuberculosis (TB) is a lung disease of worldwide prevalence. Treatment times are long and mortality is high in children and the elderly. Current treatments are ineffective and drug resistant TB is a real pandemic threat. The project will develop a cost-effective nano-particle system that can be incorporated into conventional nebulisers for use worldwide.
Development of small molecule primary sulfonamides as new drugs for malaria. Malaria is a major global health threat, causing approximately 800,000 deaths annually. Lives can be saved if patients are treated. The use of current antimalarial drugs is limited by drug resistance, low activity and poor safety. This project investigates the effectiveness of a new class of molecule as a safe drug treatment option to kill malaria parasites.
Rational design of new drug candidates for the treatment of Trypanosoma cruzi infection. There is a serious shortage of safe and effective drugs to treat Chagas disease which is caused by a parasitic infection. This project aims to design and identify new drug candidates by defining the disposition profile within the body which is necessary to achieve a therapeutic effect.
Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed ....Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed in vitro methods to better define the kinetic and dynamic activity of new drug candidates, and will provide a rational basis for translating this information into lengthy animal models of T. cruzi infection. The outcome aims to be rationally designed drug candidates that are available in a shorter period of time and are suitable for further development.Read moreRead less
Screening platforms for malaria drug discovery: identification of new therapeutics. Innovative image based technologies will be developed to identify molecules which stop malaria parasite growth and its transmission to the mosquito host. As more resistance is emerging against the current drugs of choice, new molecules acting through different mechanisms are urgently needed.
Discovery Early Career Researcher Award - Grant ID: DE120103084
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Targeting bacterial superbugs: novel approaches for optimisation of antibiotic combinations and resistance prevention. This project will elucidate the mechanistic basis to optimally combine available beta-lactam antibiotics to prevent resistance of gram-negative 'superbugs'. The interdisciplinary project will substantially contribute to solving the global crisis due to multidrug-resistant bacteria and inform the design of effective new antibiotics.
Targeting an impending global disaster: the mismatch between increasingly drug-resistant superbugs and development of new antibiotics. This project will develop much-needed novel antibiotics for treating infections caused by bacteria that are resistant to all current antibiotics. It will make a significant contribution to the global medical challenge of a shortage of new antibiotics.